Coordinated Care to Optimize Treatment in Patients With Diabetes and Cardiovascular Disease, Panitumumab vs Bevacizumab Added to Chemotherapy for Metastatic Colorectal Cancer, USPSTF Recommendation on Screening for Skin Cancer, and more
Editor’s Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the April 18, 2023, issue. Related Content: Audio Highlights (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - April 18, 2023 Category: General Medicine Authors: JAMA Network Source Type: podcasts
JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD. (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - February 2, 2023 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD. (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - December 23, 2021 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos. NSCLC vs. Tagrisso or Vizimpro
Author: cancergrace
Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2019 Category: Cancer & Oncology Source Type: podcasts
Recent Data Examining Atezolizumab And Bevacizumab In nccRCC & sccRCC
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Recent Data Examining Atezolizumab And Bevacizumab In nccRCC & sccRCC. At The 2019 G...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other trea...
Author: BeaconMedIC
Added: 08/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts
The Erlotinib/Bevacizumab Combination in EGFR Mutation-Positive Advanced NSCLC: Is Progression-Free Survival without Overall Survival Benefit Enough? (BMIC-043)
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva) with bevacizumab (Avastin), which shows a consistent improvement ...
Author: BeaconMedIC
Added: 07/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2018 Category: Cancer & Oncology Source Type: podcasts
What is the Role of Bevacizumab in Stage IV NSCLC_ [720p]
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
Author: cancergrace
Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 16, 2018 Category: Cancer & Oncology Source Type: podcasts
IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
The IMpower150 trial (NCT02366143) was the first to explore chemotherapy, immunotherapy with atezolizumab and anti-angiogenic therapy with bevacizumab for non-small cell lung cancer (NSCLC). In this i...
Author: VJOncology
Added: 04/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Two Trials looking at Inhibitors in 1st-line Therapy Combinations, Cediranib & Olapanib, and Bevacizumab & Olapanib
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Two Trials looking at Inhibitors in 1st-line Therapy Combinations, Cediranib & Olapanib, and Bevacizumab...
Author: Cancer-News
Added: 04/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib
Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib at Kidney Cancer Association 2017 in...
Author: kidneycancer
Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts
Nivolumab + Ipilimumab Front Line bevacizumab atezolizumab
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, shares thoughts on Nivoluma...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD...
Author: Genitourinary-Cancer-Meeting
Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Squamous Cell Carcinoma 4+ EGFR Carboplatin Cetuximab Safely or Bevacizumab
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses squamous cell carcinoma 4+ EGFR and giving carboplatin cetuximab safely or bevacizumab. From the 22nd Annual Perspectives in Thoracic Oncology i...
Author: thoraciconcology
Added: 01/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2018 Category: Cancer & Oncology Source Type: podcasts
T Effector Gene Signature on IMpower150: Is There a Better Biomarker than PD-L1 for Immunotherapy? (BMIC-021)
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/paclitaxel +/- bevacizumab & revealed strongest benefit of atezo in those with...
Author: BeaconMedIC
Added: 12/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 22, 2017 Category: Cancer & Oncology Source Type: podcasts
